FISH OILS LOWERED CARDIOVASCULAR RISK DESPITE AGGRESSIVE THERAPY WITH STANDARD PHARMACOTHERAPY

• The JELIS- The Japan EPA Lipid Intervention Study randomized 18645 patients with hypercholesterolemia (of which 70% were women: age 61 years) to statin alone or statin and pure EPA. EPA reduced major adverse cardiac events by 19%.


• The MAYO article also commented: Omega 3 fatty acid supplementation lowered cardiovascular risk both in GISSI-P and JELIS showed that despite aggressive therapy with standard pharmacotherapy(e.g. statins, aspirins, beta blockers, and ace inhibitors). Combination therapy with omega 3 fatty acids and a statin is a safe and effective way to improve lipid levels and cardiovascular prognosis beyond benefits provided by statin therapy alone

FISH OIL SUPPLEMENTATION REDUCES CARDIOVASCULAR EVENTS BETWEEN 19 TO 45% AND DEATH BETWEEN 28 TO 45%

1. In a recent MAYO clinic review article quotes "that the most compelling evidence for the cardiovascular benefit provided by omega-3 fatty acids comes from large controlled trials 32000 patients demonstrated in reduction in cardiovascular event between 19% to 45%.


2. In the DART Trial, omega 3 fatty acids, either in the form of oily fish or fish oil capsules, "Treatment reduced 2 year all cause mortality by 29% in post myocardial (MI) patients"


3. The GISSI-P study randomized 11,323 patients who had experienced a myocardial infarct to omega 3 acid ethyl esters (1 capsule, providing 850mg of DHA/EPA) or usual care. "Treatment reduced death from any cause by 28% after 4 months. Treatment reduced sudden cardiac death by 45%."